Business Context and Reporting Period
This Form 8-K was filed by Trxade Group, Inc. on January 5, 2017, reporting events occurring on December 31, 2016. The filing details the sale of the Company's wholly-owned subsidiary, Westminster Pharmaceuticals, LLC, which operated as the Company's wholesale and private label pharmaceutical distribution division.
Key Financial Metrics and Transaction Details
The transaction involved the sale of 100% of the equity interests in Westminster Pharmaceuticals, LLC. The consideration received by the Company included:
- Cancellation of $1,500,000 in indebtedness under a Senior Secured Note.
- Issuance of a warrant to purchase 1,500,000 shares of Common Stock at a strike price of $0.01 per share (expiring in five years).
- Cash payment of $100,000.
- Assumption of various contracts and obligations by the Buyer.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the Company or the subsidiary. The filing text does not provide a clear value for the Company's total debt or liquidity position outside of the specific note being extinguished.
Material Changes
The primary material change is the termination of a $1,500,000 Senior Secured Note (originally issued in 2015 and amended in 2016) through the asset sale. Additionally, the Company exited its pharmaceutical distribution business by divesting Westminster Pharmaceuticals, LLC to Gajan A. Mahendiran and Amudha Mahendiran.
Outlook, Risks, and Unusual Items
Pro forma financial information regarding the impact of this transaction is not included in this filing; it is scheduled to be filed via an amendment to this 8-K or in the Annual Report on Form 10-K for the period ending December 31, 2016, within 71 calendar days. The warrants issued were sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The filing notes that representations and warranties in the agreement are not intended for shareholder reliance and may apply different materiality standards than those used by investors.
Investor Verification Checklist
- Verify the pro forma financial impact of the divestiture once filed in the 10-K or 8-K amendment.
- Confirm the current status of the $1,500,000 Senior Secured Note to ensure it is fully extinguished.
- Review the full text of the Purchase and Sale Agreement (Exhibit 2.01) and Warrant Agreement (Exhibit 2.02) for specific covenants and indemnification terms.
- Assess the Company's remaining business operations following the exit from pharmaceutical distribution.